How Hormonal Disorders Affect Fertility: A Guide to Pregnancy Planning With Endocrine Conditions

Which Hormonal Disorders Most Commonly Affect Fertility?

Ovulatory dysfunction accounts for roughly one-quarter of all infertility cases, and endocrine disorders are the primary driver. PCOS is the most prevalent, affecting an estimated 8–13% of reproductive-age women according to WHO data. The condition disrupts the hypothalamic-pituitary-ovarian axis, leading to irregular or absent ovulation, elevated androgens, and metabolic complications that collectively reduce the chances of spontaneous conception.

Thyroid disorders — both hypothyroidism and hyperthyroidism — are another significant contributor. The American Thyroid Association recommends screening women with infertility or recurrent pregnancy loss for thyroid dysfunction, as even subclinical hypothyroidism (TSH above 2.5 mIU/L in early pregnancy) has been associated with reduced fertility and increased miscarriage risk. Hyperprolactinemia, often caused by pituitary adenomas, suppresses gonadotropin-releasing hormone and can halt ovulation entirely. Adrenal conditions that alter cortisol or androgen production, including non-classic forms of congenital adrenal hyperplasia, can similarly interfere with the menstrual cycle and ovulation.

What Treatment Approaches Improve Pregnancy Outcomes for Women With Endocrine Conditions?

For women with PCOS, the international evidence-based guideline endorsed by the European Society of Human Reproduction and Embryology (ESHRE) recommends letrozole as first-line ovulation induction therapy, replacing the long-standing use of clomiphene citrate. Lifestyle modifications including modest weight loss of 5–10% in women with elevated BMI have been shown to restore ovulatory cycles in a meaningful proportion of patients. Metformin may be used as an adjunct, particularly when metabolic features are prominent.

Thyroid hormone replacement with levothyroxine is straightforward and highly effective for hypothyroid women planning pregnancy, with guidelines recommending a target TSH below 2.5 mIU/L before conception. For hyperprolactinemia, dopamine agonists such as cabergoline can normalize prolactin levels and restore fertility in the majority of cases. Women with adrenal-origin androgen excess may benefit from low-dose glucocorticoid therapy to suppress excess adrenal androgens and permit normal ovulation. Across all these conditions, the evidence strongly supports preconception counseling and coordinated care between endocrinology and reproductive medicine to optimize both fertility and pregnancy safety.

Why Is Preconception Planning Critical for Women With Hormonal Conditions?

Women with endocrine disorders face elevated risks during pregnancy that extend beyond conception itself. Uncontrolled thyroid disease increases the risk of preeclampsia, preterm delivery, and neurodevelopmental effects on the fetus. PCOS is associated with a two- to threefold increased risk of gestational diabetes, according to meta-analyses published in Human Reproduction Update. Adrenal insufficiency requires careful glucocorticoid dose adjustment during pregnancy, particularly during labor and delivery when physiological stress demands rise sharply.

Preconception planning provides a window to switch medications that may be teratogenic — such as certain antithyroid drugs or ACE inhibitors used for PCOS-related hypertension — to safer alternatives. Folic acid supplementation, blood glucose optimization, and blood pressure control are all more effective when initiated before pregnancy. The American College of Obstetricians and Gynecologists (ACOG) emphasizes that women with chronic endocrine conditions should ideally consult a maternal-fetal medicine specialist before attempting conception to develop an individualized management plan.